Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 11/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | HTR1F | P30939 | 1/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9979976 | 0.89 | P2RX7 (0.44) | P2RX7CXCR2PARP1PARP2GAA | |
| SCHEMBL9980030 | 0.88 | CXCR2 (0.51) | P2RX7CXCR2PARP1PARP2 | |
| SCHEMBL9979999 | 0.85 | SMN1; SMN2 (0.40) | P2RX7PARP1PARP2GAARAB9A | |
| SCHEMBL9980001 | 0.83 | CXCR2 (0.40) | P2RX7CXCR2 | |
| SCHEMBL9980063 | 0.83 | CXCR2 (0.40) | P2RX7CXCR2 | |
| SCHEMBL9980062 | 0.78 | P2RX7 (0.47) | P2RX7CXCR2PARP1PARP2 | |
| SCHEMBL9980043 | 0.77 | CXCR2 (0.42) | CXCR2CACNA1H | |
| SCHEMBL9980029 | 0.76 | CXCR2 (0.50) | CXCR2 | |
| SCHEMBL9980067 | 0.73 | CACNA1H (0.46) | CACNA1H | |
| SCHEMBL9980054 | 0.73 | CXCR2 (0.56) | CXCR2CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651891-B1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-8648118-B2 | Bicyclic ring system substituted amide functionalised phenols as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-8648118-B2 | Bicyclic ring system substituted amide functionalised phenols as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-20120329773-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329773-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2012080456-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329773-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | CXCR2, CCR2, CCR1 | P2RX7 135/4885CXCR2 1/4885PARP1 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.